Respibron (Haemophilus influenzae, Streptococcus pneumoniae) sublingual tablets №30

Description

Respibron (Haemophilus influenzae, Streptococcus pneumoniae) sublingual tablets №30

Composition

active substance: bacterial lysate;

1 tablet contains 50 mg of lyophilized bacterial lysate, which includes 7 mg of bacterial lysate: Staphylococcus aureus 6×109 CFU, Streptococcus pyogenes 6×109 CFU, Streptococcus viridans 6×109 CFU, Klebsiella pneumoniae 6×109 CFU, Klebsiella ozaenae 6× 109 CFU, Haemophilus influenzae B 6×109 CFU, Neisseria catarrhalis 6×109 CFU, Streptococcus pneumoniae 6×109 CFU (the last bacterium contains 1×109 CFU of the following types – TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/ EQ15, TY8/EQ23, TY47/EQ24), and 43 mg of glycine for the lyophilization process;

auxiliary substances: colloidal aqueous silicon dioxide; microcrystalline cellulose; calcium hydrogen phosphate, dihydrate; magnesium stearate; ammonium glycerisinate; essence of menthol powder.

Medicinal form

Sublingual tablets.

The main physical and chemical properties: round, flat, whitish tablets with a line on one side, with brown specks, with a slight characteristic smell.

Pharmacotherapeutic group

Immunostimulants.
ATX code L03A X.

Pharmacological properties

Respibron is an immunomodulator based on bacterial lysate obtained by mechanical lysis of microbial cells. A drug that increases the body’s resistance to infections due to an increase in the number of serum and secretory antibodies, activation of cellular and humoral factors of non-specific immunity. This reduces the frequency and severity of respiratory infections, prevents the need for antibiotics.

Respibron has a double mechanism of action:

• activates non-specific resistance (rapid protection, within 2‒4 weeks from the start of taking Respibron) due to the membrane antigens included in the drug, by activating dendritic cells, neutrophils, macrophages and NK cells; induction of phagocytosis and cell lysis due to stimulation of adhesion of macrophages to bacteria;
• activates specific immunity (long-term protection, for several years) by increasing the production level of IL-2, specific serum IgA, IgG, IgM and slgA, activation of effector CD4 and CD8 T-lymphocytes, activation of B-lymphocytes.

Respibron is well absorbed in the mucous membrane of the oral cavity.

Indications

Respibron is used in the complex therapy of inflammatory diseases of the respiratory tract as an immunomodulator.
The use of this drug prevents the occurrence of recurrent infections of the respiratory tract and severe infectious exacerbations of chronic bronchitis, tracheitis, tracheobronchitis, bronchitis, bronchiectasis, COPD.
Also used as a concomitant agent in the treatment of acute respiratory infections – for influenza, rhinitis, pharyngitis, nasopharyngitis, tonsillitis, sinusitis, laryngitis, epiglotitis, sore throat.

Contraindications

The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or one of the auxiliary components.
It is not recommended to use it together with antitussives.
Used in pediatrics since 2 years.

Application during pregnancy and lactation

This drug is contraindicated in pregnant women.
If it is necessary to take the drug during breastfeeding, lactation is suspended.

Method of administration and dosage

The drug is used in the treatment of colds in the respiratory tract. The tablet dissolves under the tongue, within 1-2 minutes.

Recommended dosages:

• for prophylaxis or complex therapy: 1 tablet a day on an empty stomach for 10 consecutive days a month (the minimum course is 10 days, then repeat after 20 days);
• in the treatment of exacerbations: 1 tablet per day on an empty stomach until the symptoms disappear (the minimum course is 10 days, but not more than 30).

If the child cannot take the drug himself, the tablet can be crushed and placed in the child’s mouth.
In the case of concomitant administration with antibiotics, the drug is recommended to be used from the very beginning of treatment.
Patients with renal or hepatic insufficiency do not need dosage adjustment.

Overdose

Overdose cases were not observed.
No complications are expected in case of an overdose.

Side effects

The use of this drug can cause adverse reactions, such as, in particular:

• allergic urticaria, itching, rash;
• nausea, vomiting, diarrhea, angioedema, bronchospasm;
• peripheral edema, shortness of breath, headache;
• cough;
• increased fatigue, fever.

If side effects occur, the drug should be discontinued, symptomatic therapy should be undertaken, consult a doctor and the treatment regimen should be adjusted.